Related Experiment Videos
Single-use percutaneous catheters for intraperitoneal P32 therapy
H O Smith1, D E Gaudette, G L Goldberg
1Department of Obstetrics and Gynecology, Albert Einstein College of Medicine, Bronx, NY 10461.
Cancer
|May 15, 1994
Summary
Percutaneous catheter placement for intraperitoneal radioactive chromic phosphate (P32) therapy in ovarian and endometrial cancers is successful in most patients. This method offers a well-tolerated, effective approach without requiring additional surgery.
Area of Science:
- Oncology
- Medical Imaging
- Surgical Procedures
Background:
- Intraperitoneal (IP) radioactive chromic phosphate (P32) is an investigational treatment for ovarian and endometrial cancers.
- Percutaneously placed catheters offer a less invasive method for delivering IP P32 therapy, avoiding further surgical intervention.
Purpose of the Study:
- To evaluate the efficacy and safety of bedside percutaneous catheter placement for IP P32 administration.
- To determine the technical success rate and complication incidence associated with this procedure.
Main Methods:
- Twenty-five patients with ovarian and/or endometrial cancer underwent bedside percutaneous catheter placement using a specialized central venous catheter under local anesthesia.
- No ultrasonographic or radiologic guidance was used during catheter insertion.
- Catheter placement occurred a median of 39 days post-laparotomy.
Main Results:
- Successful catheter insertion was achieved in 88% of patients (22/25), with good IP distribution.
- The technical failure rate was 12%.
- Bowel entry occurred in 16% of patients but without clinical sequelae; increased attempts correlated with higher complication and bowel entry rates.
Conclusions:
- Percutaneous catheter placement for IP P32 therapy is a successful and well-tolerated procedure in the majority of patients.
- This technique should be considered for patients undergoing IP P32 treatment for gynecologic malignancies.